Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Sid Kerkar
10.21.26 -- Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery
Get more Advancing RNA insight with our FREE newsletter Newsletter | October 21, 2026 Webinar: Connecting the World of Oligonucleotide R&D With Early Clinical Scale Manufacturing Moving oligonucleotide production from R&D to early clinical manufacturing brings new challenges in quality, scalability, process development, and equipment.
Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases
By Sid Kerkar, MD, Founder and CEO, AllerGene AI Therapeutics My interest in applying CAR T cell therapy to allergic disease began at home. All three of my children were diagnosed with severe, life-threatening allergies, turning a disease I understood as a physician-scientist into something deeply personal.
Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases
By Sid Kerkar, MD, Founder and CEO, AllerGene AI Therapeutics My interest in applying CAR T cell therapy to allergic disease began at home. All three of my children were diagnosed with severe, life-threatening allergies, turning a disease I understood as a physician-scientist into something deeply personal.
Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases
By Sid Kerkar, MD, Founder and CEO, AllerGene AI Therapeutics My interest in applying CAR T cell therapy to allergic disease began at home. All three of my children were diagnosed with severe, life-threatening allergies, turning a disease I understood as a physician-scientist into something deeply personal.
Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion Chemotherapy
Sid Kerkar, MD, vice president of oncology and research and development at Exuma Biotech, participated in a talk called “Subcutaneous generation of synthetic lymph nodes for the in vivo production of CAR-TaNK cells” at the 7th Annual CAR-TCR Summit 2022, held September 19-22 in Boston, Massachusetts.
01.11.22 -- Why RNA Is The Spotlight Of Precision Medicine
Article | By Joe Arcangelo, inSeption Group No matter how brilliant a clinical trial process or a technology may be, it is useless without skilled, motivated individuals at the helm. Article | By Harry Benson, CAI CAI clients often seek help in closing open investigations, but ignore the source of these investigations, even while product sits quarantined. Where clients really need help is in cutting human error off at the source.
12.18.21 -- Cell and Gene Newsletter
Newsletter | December 18, 2021 By Erin Harris, editor in chief, Cell & Gene By Paul Stroemer and Paolo Siciliano, PA Consulting By Sid Kerkar, EXUMA Biotechnology By Herman & Erich Bozenhardt By Praveen Bezawada-Joseph By Joe Makowiecki and Harlan Knapp By James Brown, Ph.D. By Joe Hoff By Jeff Hall and Lisa Hawkins By Martin Wisher, Manjula Aysola, and Natika Calhoun By Mark White AES Clean Technology, Inc. MasterControl, Inc.
12.16.21 -- The Evolution, Challenge, And Hope Of CAR-T Therapy
Article | By Dawn Niccum, inSeption Group Effective risk management recognizes variables unique to each clinical trial while embracing consistent documentation practices, stakeholder responsibility, and best practices informed by experience.
A First-Hand Account: The Evolution, Challenge, And Hope Of CAR-T Therapy
By Sid Kerkar, VP, Research and Development, EXUMA Biotechnology My first introduction to Cancer Immunotherapy was in 2005 during my second year of general surgery residency in Detroit, Michigan. I had just finished an overnight shift when I learned that a chief resident from my intern year passed away from widespread Stage IV metastatic colorectal cancer. He spent a majority of his life training to become a surgeon and now he was gone.
A First-Hand Account: The Evolution, Challenge, And Hope Of CAR-T Therapy
By Sid Kerkar, VP, Research and Development, EXUMA Biotechnology My first introduction to Cancer Immunotherapy was in 2005 during my second year of general surgery residency in Detroit, Michigan. I had just finished an overnight shift when I learned that a chief resident from my intern year passed away from widespread Stage IV metastatic colorectal cancer. He spent a majority of his life training to become a surgeon and now he was gone.
Economically Viable, Same-Day Autologous Cell Therapies
Cell therapies, particularly chimeric antigen receptor (CAR) T cell therapies, are highly complex and autologous therapies, and those on the market today require weeks to manufacture from the time a patient sample is obtained. One of the major challenges facing CAR-T cell therapy is the cost and complexity to deliver these treatments.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Sid
Contact Sid, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack